Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content
Cancer PHGKB

Specific PHGKB|Cancer|PHGKB
Last Posted: Mar 28, 2023
spot light Spotlight

Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy.
Margaret R Smith et al. NPJ precision oncology 2023 3 (1) 34

Different types of therapy are currently being used to treat non-small cell lung cancer (NSCLC) depending on the stage of tumor and the presence of potentially druggable mutations. However, few biomarkers are available to guide clinicians in selecting the most effective therapy for all patients with various genetic backgrounds. To examine whether patients’ mutation profiles are associated with the response to a specific treatment, we collected comprehensive clinical characteristics and sequencing data from 524 patients with stage III and IV NSCLC.

Evaluating Colonoscopy Screening Intervals in Patients with Lynch Syndrome from a Large Canadian Registry
M Aronson et al, JNCI, March 25, 2023

Lynch Syndrome (LS) screening guidelines originally recommended colonoscopy every 1 to 2 years, beginning between the ages of 20-25 years. Recent studies have questioned the benefits of these short screening intervals in preventing colorectal cancer (CRC). A total of 429 patients with LS were identified with median follow-up of 9.2 years, 44 developed CRC. We found a positive trend between shorter screening intervals and the number of adenomas detected during colonoscopy. Any new adenoma detected at screening decreased 10-year CRC incidence by 11.3%. For MLH1 carriers, a screening interval of 1-2 years vs. 2-3 years led to a 20-year cumulative CRC risk reduction of 28% and 14% in females and males.

Top advances of the year: Precision oncology.
Aakash Desai et al. Cancer 2023 3

In this review, recent major developments in precision oncology that have affected outcomes for patients with cancer are discussed. Rapid clinical development was seen of targeted agents across various mutational profiles such as KRASG12C (which was considered “undruggable” for almost 4 decades), Exon 20 insertions, and RET mutations. Approaches to precision chemotherapy delivery by the introduction of antibody drug conjugates in the armamentarium against lung cancer has been appreciated.

Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database
MD Valentin et al, EClinicalMedicine, March 2023

The Prospective Lynch Syndrome Database (PLSD) collates information on carriers of pathogenic or likely pathogenic MMR variants (path_MMR) who are receiving medical follow-up, including colonoscopy surveillance, which aims to the achieve early diagnosis and treatment of cancers. In path_MMR carriers undergoing colonoscopy surveillance, non-colorectal Lynch syndrome cancers were associated with more deaths than were colorectal cancers. Reducing deaths from non-colorectal cancers presents a key challenge in contemporary medical care in Lynch syndrome.

news Latest News and Publications
Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment. External Web Site Icon
Fionnuala Crowley et al. The oncologist 2023
Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations. External Web Site Icon
Francesco Cortiula et al. European journal of cancer (Oxford, England : 1990) 2023 184172-178
Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer. External Web Site Icon
Yongcheng Chen et al. Gland surgery 2023 12(2) 197-207
CACSV: a computational web-sever that provides classification for cancer somatic genetic variants from different tissues. External Web Site Icon
Nahla AlKurabi et al. BMC bioinformatics 2023 24(1) 95
Cascade Genetic Risk Education and Testing in Families With Hereditary Cancer Syndromes: A Pilot Study. External Web Site Icon
Steven J Katz et al. JCO oncology practice 2023 OP2200677
Clinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols. External Web Site Icon
Zihui Yang et al. BMC cancer 2023 23(1) 243
Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. External Web Site Icon
Katherine I Foster et al. Cancer 2023
Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital. External Web Site Icon
Sandra Pinet et al. Frontiers in oncology 2023 131104659
Concordance between 21-gene recurrence score assay and clinicopathological predictive models in early-breast cancer patients cared for at a cancer center in Colombia. External Web Site Icon
Mauricio Luján et al. Gaceta medica de Mexico 2023 159(1) 3-9
Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary. External Web Site Icon
Xin Wang et al. The oncologist 2023


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.